Form 4: Immix Biopharma CFO Gabriel Morris Reports Stock Option Grant and Beneficial Ownership Changes

CFO Gabriel Morris reports the acquisition of stock options and changes in beneficial ownership of Immix Biopharma, Inc. shares.

Summary

• Gabriel Morris, CFO of Immix Biopharma, Inc., filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• The report indicates that Mr. Morris was granted stock options to purchase 340,000 shares of common stock at an exercise price of $2.04 on June 11, 2024.
• These options will vest in 48 equal monthly installments, contingent upon his continued service with the company.
• The report also reflects Mr. Morris's direct ownership of 285,834 shares of common stock.
• Additionally, it notes his indirect ownership of 270,844 shares through Alwaysraise LLC and 24,141 shares through Alwaysraise Ventures I, LP.
• Mr. Morris disclaims beneficial ownership of the indirectly held shares except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants and beneficial ownership. The grant itself can be seen as a positive sign of aligning management incentives, but the filing is primarily informational.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedule of the options encourages long-term commitment from the CFO.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates compensation and ownership structure for a key executive.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CFO.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates